Guardant Health Inc (NASDAQ:GH) was down 7.1% during trading on Friday . The company traded as low as $78.35 and last traded at $79.01. Approximately 1,401,195 shares changed hands during mid-day trading, an increase of 112% from the average daily volume of 660,039 shares. The stock had previously closed at $85.07.

GH has been the subject of a number of recent research reports. Bank of America reissued a “neutral” rating and set a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a research report on Thursday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a report on Wednesday, March 13th. Finally, Zacks Investment Research downgraded shares of Guardant Health from a “hold” rating to a “sell” rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $72.50.

The firm has a market cap of $6.79 billion and a price-to-earnings ratio of -28.22.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The business had revenue of $32.87 million during the quarter, compared to analyst estimates of $24.57 million. Analysts predict that Guardant Health Inc will post -1.45 earnings per share for the current year.

In other Guardant Health news, major shareholder Vision Fund (Aiv M1) Softbank acquired 2,033,990 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was purchased at an average price of $9.83 per share, for a total transaction of $19,994,121.70. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Temasek Holdings Private Ltd acquired a new position in Guardant Health during the 4th quarter worth approximately $60,633,000. Orbimed Advisors LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $57,681,000. BlackRock Inc. acquired a new position in Guardant Health during the 4th quarter worth approximately $41,894,000. Jennison Associates LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $31,700,000. Finally, Lord Abbett & CO. LLC acquired a new position in Guardant Health during the 4th quarter worth approximately $20,024,000. Institutional investors own 69.54% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Guardant Health (GH) Stock Price Down 7.1%” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2019/03/24/guardant-health-gh-stock-price-down-7-1.html.

Guardant Health Company Profile (NASDAQ:GH)

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

See Also: 12b-1 Fees

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.